Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE: Pegcetacoplan in Preventing Disease Recurrence in Kidney Transplant Recipients
NCT07898774Phase 3Not yet recruiting
- Sponsor
- Sobi
- Start
- Jan 2027
- Primary completion
- Jan 2031
- Countries
- 10
01
Overview
A Phase 3 trial of pegcetacoplan in Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Sobi. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT07898774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898774.